International Clinical Trial: A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07726992) titled 'A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Condition: Papillary-Only Non-muscle-invasive Bladder Cancer

Intervention: Drug: SHR-1501+BCG

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: July 2026

Target Sample Size: 750

Cou...